Regeneron Pharmaceuticals Inc. sell Bank of America Co.
Summary
This prediction ended on 30.03.24 with a price of €902.40. The prediction closed with a disappointing performance of 19.37%. Bank_of_America_Co_ has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Sell. Bank_of_America_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Regeneron Pharmaceuticals Inc. | -3.156% | -3.156% | 47.282% |
iShares Core DAX® | -0.116% | 1.953% | 14.155% |
iShares Nasdaq 100 | -2.733% | -1.273% | 31.828% |
iShares Nikkei 225® | -1.721% | 3.263% | 12.922% |
iShares S&P 500 | -1.527% | 0.194% | 27.117% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
12.04.24
12.04.25
23.07.24